Shopping Cart
Remove All
Your shopping cart is currently empty
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | In Stock | In Stock | |
| 2 mg | $229 | - | In Stock | |
| 5 mg | $413 | In Stock | In Stock | |
| 10 mg | $662 | - | In Stock | |
| 25 mg | $987 | - | In Stock | |
| 50 mg | $1,330 | - | In Stock | |
| 100 mg | $1,790 | - | In Stock |
| Description | Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. |
| Targets&IC50 | α4β1/α4β7 - MadCAM-1-Ig:0.35 ± 0.04 nM, α4β1:19.6 nM (KD), α4β1:0.11 ± 0.01 μg/mL (EC50), α4β1/α4β7 - VCAM-1-Ig:0.196 nM, α4β1/α4β7 - Fibronectin:0.32 nM |
| In vitro | Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin.As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin[1]. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Integrin a4/ITGA4/CD49d |
| Molecular Weight | 146.19 kDa |
| Cas No. | 189261-10-7 |
| Relative Density. | no data available |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.